Drug Innovation
Commentary
The Senate should reject foreign drug importation
Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the ...
Commentary
To Cure Rare Diseases, Unleash Orphan Drug Innovations
Last month, the City of Pittsburgh hosted the 35th annual Great Race, a charity run that raises money for the Richard S. Caliguiri Amyloidosis Research Fund. Caliguiri, a former Pittsburgh mayor, died of this rare protein disorder, and a portion of the race proceeds are used to help find a ...
Business & Economics
Putting Drug Research in Legal Jeopardy
The U.S. Supreme Court’s recent ruling in Wyeth v. Levine—holding that drug manufacturers are not free of liability under state law, even when the drug in question has secured federal regulatory approval—has worried pharmaceutical manufacturers, who can now face crippling state tort lawsuits despite being in regulatory compliance. A less-noticed ...
The Senate should reject foreign drug importation
Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the ...
To Cure Rare Diseases, Unleash Orphan Drug Innovations
Last month, the City of Pittsburgh hosted the 35th annual Great Race, a charity run that raises money for the Richard S. Caliguiri Amyloidosis Research Fund. Caliguiri, a former Pittsburgh mayor, died of this rare protein disorder, and a portion of the race proceeds are used to help find a ...
Putting Drug Research in Legal Jeopardy
The U.S. Supreme Court’s recent ruling in Wyeth v. Levine—holding that drug manufacturers are not free of liability under state law, even when the drug in question has secured federal regulatory approval—has worried pharmaceutical manufacturers, who can now face crippling state tort lawsuits despite being in regulatory compliance. A less-noticed ...
